Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWAYNASDAQ:IRMDNASDAQ:RXSTNASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsWay$10.31-1.4%$9.28$5.67▼$11.79$194.57M1.2566,621 shs30,216 shsIRMDIradimed$60.36-0.7%$52.80$41.71▼$63.29$767.48M0.9143,279 shs58,418 shsRXSTRxSight$14.92-2.2%$15.58$12.53▼$60.81$606.30M1.29699,597 shs533,133 shsSIBNSI-BONE$19.06+3.1%$15.90$11.70▼$20.05$812.24M0.82380,941 shs1.06 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsWay+2.65%-2.24%+20.09%+14.07%+52.03%IRMDIradimed+1.66%+17.65%+16.21%+16.01%+42.14%RXSTRxSight-3.48%-5.22%+4.23%-40.30%-73.24%SIBNSI-BONE-2.17%0.00%+29.75%+13.02%+34.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBWAYBrainsWay3.1105 of 5 stars3.53.00.00.02.70.81.9IRMDIradimed4.7817 of 5 stars2.53.02.54.43.93.31.9RXSTRxSight2.9842 of 5 stars4.21.00.00.03.12.50.6SIBNSI-BONE3.8656 of 5 stars2.53.00.03.34.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWAYBrainsWay 3.00Buy$14.2538.22% UpsideIRMDIradimed 3.00Buy$72.0019.28% UpsideRXSTRxSight 2.30Hold$37.90154.02% UpsideSIBNSI-BONE 3.00Buy$22.5018.05% UpsideCurrent Analyst Ratings BreakdownLatest BWAY, SIBN, IRMD, and RXST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $25.005/6/2025SIBNSI-BONETruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.005/6/2025SIBNSI-BONECantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/6/2025SIBNSI-BONENeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/15/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.004/9/2025RXSTRxSightUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$45.00 ➝ $16.004/4/2025RXSTRxSightJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Underweight$40.00 ➝ $17.004/3/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$35.00 ➝ $22.004/3/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$36.00 ➝ $22.004/3/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$43.00 ➝ $43.003/21/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $36.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWAYBrainsWay$43.46M4.48N/AN/A$2.50 per share4.12IRMDIradimed$75.15M10.21$1.50 per share40.12$5.66 per share10.66RXSTRxSight$148.31M4.09N/AN/A$4.47 per share3.34SIBNSI-BONE$176.60M4.60N/AN/A$4.18 per share4.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWAYBrainsWay-$4.20M$0.20103.1164.44N/A3.88%3.52%2.26%8/5/2025 (Estimated)IRMDIradimed$19.23M$1.5540.2430.18N/A26.26%24.12%21.20%7/30/2025 (Estimated)RXSTRxSight-$48.61M-$0.67N/AN/AN/A-23.92%-14.00%-12.51%8/4/2025 (Estimated)SIBNSI-BONE-$43.34M-$0.64N/AN/AN/A-23.82%-22.51%-16.53%8/4/2025 (Estimated)Latest BWAY, SIBN, IRMD, and RXST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BWAYBrainsWay$0.02$0.04+$0.02$0.04$11.45 million$11.54 million5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 million5/5/2025Q1 2025SIBNSI-BONE-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWAYBrainsWayN/AN/AN/AN/AN/AIRMDIradimed$0.681.13%N/A43.87%1 YearsRXSTRxSightN/AN/AN/AN/AN/ASIBNSI-BONEN/AN/AN/AN/AN/ALatest BWAY, SIBN, IRMD, and RXST DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025IRMDIradimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWAYBrainsWayN/A4.524.23IRMDIradimedN/A9.217.82RXSTRxSightN/A12.6711.71SIBNSI-BONE0.228.257.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWAYBrainsWay30.11%IRMDIradimed92.34%RXSTRxSight78.78%SIBNSI-BONE98.11%Insider OwnershipCompanyInsider OwnershipBWAYBrainsWay19.00%IRMDIradimed36.80%RXSTRxSight9.36%SIBNSI-BONE4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWAYBrainsWay12018.87 million15.24 millionNot OptionableIRMDIradimed11012.72 million7.97 millionOptionableRXSTRxSight22040.64 million36.53 millionOptionableSIBNSI-BONE35042.62 million40.30 millionOptionableBWAY, SIBN, IRMD, and RXST HeadlinesRecent News About These CompaniesSquarepoint Ops LLC Buys Shares of 32,060 SI-BONE, Inc. (NASDAQ:SIBN)June 5 at 4:04 AM | marketbeat.comSI-BONE to Truist Securities MedTech Conference on June 17, 2025June 4 at 4:30 PM | globenewswire.comWellington Management Group LLP Sells 523,551 Shares of SI-BONE, Inc. (NASDAQ:SIBN)June 4 at 4:22 AM | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) Stock Position Increased by Bank of America Corp DEJune 4 at 3:24 AM | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Two Sigma Advisers LPJune 1, 2025 | marketbeat.com15,454 Shares in SI-BONE, Inc. (NASDAQ:SIBN) Bought by Man Group plcMay 29, 2025 | marketbeat.comSI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025May 28, 2025 | globenewswire.comSI-BONE’s SWOT analysis: stock poised for growth amid market expansionMay 28, 2025 | investing.comWall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?May 26, 2025 | zacks.comNuveen Asset Management LLC Has $17.72 Million Stake in SI-BONE, Inc. (NASDAQ:SIBN)May 26, 2025 | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Lazard Asset Management LLCMay 23, 2025 | marketbeat.comNorthern Trust Corp Increases Holdings in SI-BONE, Inc. (NASDAQ:SIBN)May 23, 2025 | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) Shares Acquired by Paradigm Capital Management Inc. NYMay 22, 2025 | marketbeat.comVirtus Investment Advisers Inc. Acquires Shares of 13,950 SI-BONE, Inc. (NASDAQ:SIBN)May 21, 2025 | marketbeat.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 2,424 Shares of StockMay 21, 2025 | insidertrades.comSilvercrest Asset Management Group LLC Boosts Position in SI-BONE, Inc. (NASDAQ:SIBN)May 19, 2025 | marketbeat.comMercer Global Advisors Inc. ADV Invests $210,000 in SI-BONE, Inc. (NASDAQ:SIBN)May 19, 2025 | marketbeat.comGraham Capital Management L.P. Invests $498,000 in SI-BONE, Inc. (NASDAQ:SIBN)May 18, 2025 | marketbeat.comSI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 4,937 SharesMay 17, 2025 | marketbeat.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 4,937 Shares of StockMay 16, 2025 | insidertrades.comParkman Healthcare Partners LLC Acquires 31,284 Shares of SI-BONE, Inc. (NASDAQ:SIBN)May 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBWAY, SIBN, IRMD, and RXST Company DescriptionsBrainsWay NASDAQ:BWAY$10.31 -0.15 (-1.43%) Closing price 04:00 PM EasternExtended Trading$10.18 -0.14 (-1.31%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Iradimed NASDAQ:IRMD$60.36 -0.42 (-0.69%) Closing price 04:00 PM EasternExtended Trading$60.64 +0.28 (+0.46%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.RxSight NASDAQ:RXST$14.92 -0.34 (-2.23%) Closing price 04:00 PM EasternExtended Trading$14.92 +0.01 (+0.03%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.SI-BONE NASDAQ:SIBN$19.06 +0.57 (+3.08%) Closing price 04:00 PM EasternExtended Trading$19.07 +0.01 (+0.03%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
